ReSync Bio
ReSync Bio was a San Francisco-based scientific software company that provided biopharmaceutical R&D teams with no-code access to AI drug discovery tools, including NVIDIA BioNeMo. Founded in 2024, it was acquired by Benchling in August 2025, with the ReSync platform subsequently sunset.
- Company typePrivate
- Founded2024
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What ReSync Bio does
ReSync Bio was a San Francisco-based scientific software company founded in 2024 that built a no-code AI platform for biopharmaceutical drug discovery teams. The platform provided scientists with direct access to advanced AI capabilities—including NVIDIA BioNeMo and open-source drug discovery models such as Boltz and REINVENT4—without requiring them to construct their own underlying AI infrastructure. Its core value proposition was enabling R&D teams to move faster from idea to insight and from digital to experimental phases through data coordination and collaboration tools targeting preclinical research workflows.
The company operated an enterprise SaaS model aimed at pharmaceutical and biotechnology R&D organizations, with planned commercialization funded by an undisclosed September 2024 financing round. Headcount was small (1–10 employees), and the company explicitly described itself as a tight-knit team of five members (Mihir, Nishanth, Lindsay, Tony, Chelsea). Specific pricing, revenue figures, and named customer logos were not publicly disclosed; partnerships with NVIDIA BioNeMo (core) and Rowan (supporting) were the primary commercial ecosystem anchors.
In August 2025, ReSync Bio was acquired by Benchling, a scientific R&D platform serving hundreds of thousands of scientists. Following the acquisition, the ReSync standalone platform is being sunset and customers are being transitioned to Benchling, effectively ending ReSync Bio's independent operations roughly twelve months after founding.
ReSync Bio firmographics
Firmographics- Name
- ReSync Bio
- Legal name
- ReSync Bio
- Website
- https://resync.bio
- Company type
- Private
- Founded year
- 2024
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- ReSync Bio was a San Francisco-based scientific software company that provided biopharmaceutical R&D teams with no-code access to AI drug discovery tools, including NVIDIA BioNeMo. Founded in 2024, it was acquired by Benchling in August 2025, with the ReSync platform subsequently sunset.
- Ownership category
- akta.pro rank
ReSync Bio industry classification
Industry- Product category
- Drug Discovery Software
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where ReSync Bio is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ReSync Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Scientific Software Platform: SaaS platform providing data coordination and collaboration tools for biopharma companies to accelerate preclinical R&D
Go-to-market motion1 record
Distribution channels1 record
ReSync Bio product offering
Product offeringCore offering
ReSync Bio provided biopharmaceutical companies with a scientific software platform that gave scientists no-code access to advanced AI tools for drug discovery and preclinical research. The platform combined industry partnerships (NVIDIA BioNeMo), open-source tools (Boltz, REINVENT4), and commercial partners (Rowan) to accelerate data coordination and collaboration across preclinical R&D workflows. The standalone platform is being sunset following the company's August 2025 acquisition by Benchling.
Product overview
ReSync Bio offered a unified drug discovery platform providing scientists with no-code access to advanced AI tools. The platform integrated industry partnerships (NVIDIA BioNeMo) and open-source tools (Boltz, REINVENT4) to help biotech companies accelerate preclinical R&D through data coordination and collaboration. The company has since been acquired by Benchling, and the ReSync platform will be sunsetted over the coming months as customers transition to Benchling.
Differentiator
Problem solved
Functional benefit
Products and services
- ReSync Bio Drug Discovery Platform
Companies that use ReSync Bio
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
ReSync Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature1 record
ReSync Bio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core, supporting and flagship.
- NVIDIA BioNeMocoreIndustry partnership providing AI infrastructure for drug discovery. NVIDIA BioNeMo is part of ReSync Bio's ecosystem of tools that gave scientists no-code access to advanced AI capabilities.
- RowansupportingCommercial partner providing additional capabilities within the ReSync Bio ecosystem for scientist access to AI tools.
- BenchlingflagshipReSync Bio was acquired by Benchling as part of Benchling's strategy to scale AI-powered drug discovery tools. Benchling serves hundreds of thousands of scientists and offers platform infrastructure for ReSync's technology to accelerate workflows across the industry.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
ReSync Bio competitors and assessment
Company assessmentDirect peers
- Valo Health: AI-powered drug discovery platform integrating data, computation, and wet-lab validation. Comparable as an AI-first biopharma tooling vendor targeting preclinical discovery.
- XtalPi: AI + robotics drug discovery platform combining computation with automated experimentation. Comparable as an enterprise AI drug-discovery vendor serving global biopharma.
- Schrödinger: Physics-based computational chemistry and AI platform used by biopharma for molecular design and preclinical discovery. Comparable as a software-first AI/ML drug discovery vendor with subscription SaaS revenue model.
- Atomwise: AI small-molecule discovery platform serving biopharma with proprietary models (AtomNet). Comparable as an AI drug-discovery vendor targeting preclinical workflows and biopharma customers.
- Recursion Pharmaceuticals: Publicly-listed AI drug discovery company combining high-throughput biology with machine learning for preclinical R&D. Comparable scale, mission, and target customers (large biopharma).
- Insitro: AI-driven drug discovery platform combining machine learning with biology for preclinical R&D. Directly comparable as an AI-for-biopharma platform targeting similar enterprise customers and similar stages of the discovery workflow.
Emerging players
- Owkin: AI platform for biomedical research and drug development, focused on federated learning and translational research. Comparable as a vendor applying AI/ML tools to biopharma R&D workflows.
- Iambic Therapeutics: AI-driven drug discovery platform with proprietary models for molecular generation. Comparable as an emerging AI-native biopharma tooling vendor targeting preclinical R&D.
- Cradle.bio: AI platform for protein engineering and design, used by biotech and biopharma teams. Comparable as an emerging no-code / scientist-friendly AI tool for preclinical biology.
Broad incumbents
- Benchling: Acquirer and now parent of ReSync Bio. Benchling is the dominant cloud lab-informatics platform serving hundreds of thousands of scientists. Closest peer because ReSync's tooling is being absorbed directly into Benchling's AI roadmap.
Market position
Strengths4 records
Weaknesses3 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
ReSync Bio social profiles
Digital presenceReSync Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
ReSync Bio leadership team
Management profileNumber of profiles
Profiles1 record
ReSync Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ReSync Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ReSync Bio
What does ReSync Bio do?
ReSync Bio provided biopharmaceutical companies with a scientific software platform that gave scientists no-code access to advanced AI tools for drug discovery and preclinical research. The platform combined industry partnerships (NVIDIA BioNeMo), open-source tools (Boltz, REINVENT4), and commercial partners (Rowan) to accelerate data coordination and collaboration across preclinical R&D workflows. The standalone platform is being sunset following the company's August 2025 acquisition by Benchling.
Is ReSync Bio a public or private company?
ReSync Bio is a private company. It is classified as corporate owned and is currently acquired.
When was ReSync Bio founded?
ReSync Bio was founded in 2024. It employs 1 to 10 people.
Where is ReSync Bio based?
ReSync Bio is headquartered in San Francisco, United States, in the North America region.
How does ReSync Bio make money?
One revenue line is on record: scientific Software Platform.
Who are ReSync Bio's main competitors?
Direct peers on record are Valo Health, XtalPi, Schrödinger, Atomwise, Recursion Pharmaceuticals and Insitro. Emerging players are Owkin, Iambic Therapeutics and Cradle.bio. Benchling is listed as a broad incumbent.
Does ReSync Bio have an API?
No public API is recorded for ReSync Bio.
What industry is ReSync Bio in?
ReSync Bio's product category is Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 54151 and its SIC code is 7372.